Retroperitoneal fibrosis

被引:608
作者
Vaglio, A
Salvarani, C
Buzio, C
机构
[1] Univ Parma, Dept Clin Med Nephrol & Hlth Sci, I-43100 Parma, Italy
[2] Arcispedale S Maria Nuova, Rheumatol Serv, Reggio Emilia, Italy
关键词
D O I
10.1016/S0140-6736(06)68035-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Retroperitoneal fibrosis encompasses a range of diseases characterised by the presence of a fibro-inflammatory tissue, which usually surrounds the abdominal aorta and the iliac arteries and extends into the retroperitoneum to envelop neighbouring structures-eg, ureters. Retroperitoneal fibrosis is generally idiopathic, but can also be secondary to the use of certain drugs, malignant diseases, infections, and surgery. Idiopathic disease was thought to result from a local inflammatory reaction to antigens in the atherosclerotic plaques of the abdominal aorta, but clinicolaboratory findings-namely, the presence of constitutional symptoms and the high concentrations of acute-phase reactants-and the frequent association of the disease with autoimmune diseases that involve other organs suggest that it might be a manifestation of a systemic autoimmune or inflammatory disease. Steroids are normally used to treat idiopathic retroperitoneal fibrosis, although other options g, immunosuppressants, tamoxifen-are available. The outlook is usually good, but, if not appropriately diagnosed or treated, the disease can cause severe complications, such as end-stage renal failure. Here, we review the different aspects of retroperitoneal fibrosis, focusing on idiopathic retroperitoneal fibrosis and on the differential diagnosis associated with the secondary forms.
引用
收藏
页码:241 / 251
页数:11
相关论文
共 103 条
[1]   Diagnosis and management of pergolide-induced fibrosis [J].
Agarwal, P ;
Fahn, S ;
Frucht, SJ .
MOVEMENT DISORDERS, 2004, 19 (06) :699-704
[2]   METHYLDOPA AND RETROPERITONEAL FIBROSIS [J].
AHMAD, S .
AMERICAN HEART JOURNAL, 1983, 105 (06) :1037-1038
[3]  
Al-Musawi D, 1998, BRIT J UROL, V82, P442
[4]  
Albarran J., 1905, ASS FRANC UROL, V9, P511
[5]   Hashimoto's thyroiditis and Graves' disease associated with retroperitoneal fibrosis [J].
Armigliato, M ;
Paolini, R ;
Bianchini, E ;
Monesi, G ;
Zamboni, S ;
D'Andrea, E .
THYROID, 2002, 12 (09) :829-831
[6]   MALIGNANT VERSUS NONMALIGNANT RETROPERITONEAL FIBROSIS - DIFFERENTIATION WITH MR IMAGING [J].
ARRIVE, L ;
HRICAK, H ;
TAVARES, NJ ;
MILLER, TR .
RADIOLOGY, 1989, 172 (01) :139-143
[7]   IDIOPATHIC RETROPERITONEAL FIBROSIS - A RETROSPECTIVE ANALYSIS OF 60 CASES [J].
BAKER, LRI ;
MALLINSON, WJW ;
GREGORY, MC ;
MENZIES, EAD ;
CATTELL, WR ;
WHITFIELD, HN ;
HENDRY, WF ;
WICKHAM, JEA ;
JOEKES, AM .
BRITISH JOURNAL OF UROLOGY, 1987, 60 (06) :497-503
[8]   Long-term outcome after inflammatory abdominal aortic aneurysm repair: Case-matched study [J].
Bonati, L ;
Rubini, P ;
Japichino, GG ;
Parolari, A ;
Contini, S ;
Zinicola, R ;
Fusari, M ;
Biglioli, P .
WORLD JOURNAL OF SURGERY, 2003, 27 (05) :539-544
[9]   Treatment of idiopathic retroperitoneal fibrosis with tamoxifen [J].
Bourouma, R ;
Chevet, D ;
Michel, F ;
Cercueil, JP ;
Arnould, L ;
Rifle, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (11) :2407-2410
[10]  
Chander Subhash, 2002, Mol Imaging Biol, V4, P363, DOI 10.1016/S1536-1632(02)00021-5